title: Effect of vasoactive intestinal peptide on pulmonary surfactants phospholipid synthesis in lung explants.
abstract: OBJECTIVE
  To investigate the effect of vasoactive intestinal peptide (VIP) on pulmonary surfactants (PS) phospholipid synthesis in cultured lung explants.
  
  
  METHODS
  Lung explants were cultured with serum-free medium, [methyl-3H]choline incorporation, total phospholipid, phosphatidylcholine, activity of choline-phosphate cytidylyltransferase (CCT) and CCTalpha mRNA level in lung explants were determined.
  
  
  RESULTS
  (1) VIP (10(-10)-10(-7) mol/L) for 16 h promoted [methyl-3H]choline incorporation in dose dependence and VIP (10(-8) mol/L) for 2 h-16 h promoted [methyl-3H]choline incorporation in time dependence. (2) VIP (10(-8) mol/L) enhanced the contents of total phospholipids and phosphatidylcholine in lung explants. (3) VIP (10(-10)-10(-7) mol/L) elevated microsomal CCT activity of lung explants in dose dependence. (4) VIP (10(-8) mol/L) increased expression of CCTalpha mRNA in lung explants and alveolar type II cells (ATII). (5) [D-P-Cl-Phe(6)-Leu(17)]-VIP (10(-6) mol/L), a VIP receptors antagonist, abolished the increase of [3H]choline incorporation, microsomal CCT activity and CCTalpha mRNA level induced by VIP (10(-8) mol/L) in lung explants.
  
  
  CONCLUSIONS
  VIP could enhance synthesis of phosphatidylcholine, the major component of pulmonary surfactants by enhancing microsomal CCT activity and CCTalpha mRNA level via VIP receptor-mediated pathway.
authors.affiliation: Department of Physiology, Xiangya School of Medicine, Central South University, Changsha 410078, China.
authors.forename: Lian
authors.initials: L
authors.lastname: Li
authors.forename: Zi-qiang
authors.initials: ZQ
authors.lastname: Luo
authors.forename: Fu-wen
authors.initials: FW
authors.lastname: Zhou
authors.forename: Dan-dan
authors.initials: DD
authors.lastname: Feng
authors.forename: Cha-xiang
authors.initials: CX
authors.lastname: Guang
authors.forename: Chang-qing
authors.initials: CQ
authors.lastname: Zhang
authors.forename: Xiou-hong
authors.initials: XH
authors.lastname: Sun
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D002794:Choline / Q000096:biosynthesis; D019916:Choline-Phosphate Cytidylyltransferase / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D007527:Isoenzymes / Q000096:biosynthesis / Q000235:genetics; D008168:Lung / Q000166:cytology / Q000201:enzymology*; D008297:Male; D008861:Microsomes / Q000201:enzymology; D010713:Phosphatidylcholines / Q000096:biosynthesis; D010743:Phospholipids / Q000096:biosynthesis; D011663:Pulmonary Surfactants / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D018005:Receptors, Vasoactive Intestinal Peptide / Q000037:antagonists & inhibitors; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
chemical_list: D007527:Isoenzymes; D010713:Phosphatidylcholines; D010743:Phospholipids; D011663:Pulmonary Surfactants; D012333:RNA, Messenger; D018005:Receptors, Vasoactive Intestinal Peptide; C048507:vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-; D014660:Vasoactive Intestinal Peptide; D019916:Choline-Phosphate Cytidylyltransferase; D002794:Choline